Contract facts
NONEDEVELOPING UNIVERSAL CONTROL PEPTIDES FOR T-CELL ASSAYS SUPPORTING IMMUNOGENICITY is a federal NONE award for Fda Office Of Acq Grant Svcs held by Cubrc, Inc. Estimated value $2.2M ($1.3M obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: BUFFALO NY.
DEVELOPING UNIVERSAL CONTROL PEPTIDES FOR T-CELL ASSAYS SUPPORTING IMMUNOGENICITY
Recompete timing
PublicCurrent PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordCubrc, Inc — $54.5M obligated across 48 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40124C00094?
75F40124C00094 (Developing universal control peptides for t-cell) is a Fda Office Of Acq Grant Svcs award with a potential value of $2.2M, currently held by Cubrc, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40124C00094?
Fda Office Of Acq Grant Svcs awarded 75F40124C00094 to Cubrc, Inc (potential $2.2M).
Who is the incumbent on 75F40124C00094?
Cubrc, Inc is the incumbent with $54.5M across 48 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Cubrc, Inc’s 75F40124C00094 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.